Search Results - "Coteur, G" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

by Landewé, R, Braun, J, Deodhar, A, Dougados, M, Maksymowych, W P, Mease, P J, Reveille, J D, Rudwaleit, M, van der Heijde, D, Stach, C, Hoepken, B, Fichtner, A, Coteur, G, de Longueville, M, Sieper, J
Published in Annals of the rheumatic diseases (01.01.2014)

Get full text

Journal Article

Re-Validation of the Self-Injection Assessment Questionnaire© (Siaqv2.0©) in Rheumatoid Arthritis Patients on Certolizumab Pegol Treatment

Re-Validation of the Self-Injection Assessment Questionnaire© (Siaqv2.0©) in Rheumatoid Arthritis Patients on Certolizumab Pegol Treatment

by Coteur, G
Published in Value in health (01.11.2014)

Get full text

Journal Article

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study

Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study

by Gladman, D., Fleischmann, R., Coteur, G., Woltering, F., Mease, P. J.
Published in Arthritis care & research (2010) (01.07.2014)

Get full text

Journal Article

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

by Reich, K., Ortonne, J.-P., Gottlieb, A.B., Terpstra, I.J., Coteur, G., Tasset, C., Mease, P.
Published in British journal of dermatology (1951) (01.07.2012)

Get full text

Journal Article

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

by Fleischmann, R, Vencovsky, J, van Vollenhoven, R F, Borenstein, D, Box, J, Coteur, G, Goel, N, Brezinschek, H-P, Innes, A, Strand, V
Published in Annals of the rheumatic diseases (01.06.2009)

Get full text

Journal Article

Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease

Evaluation of the meaningfulness of health‐related quality of life improvements as assessed by the SF‐36 and the EQ‐5D VAS in patients with active Crohn’s disease

by COTEUR, G., FEAGAN, B., KEININGER, D. L., KOSINSKI, M.
Published in Alimentary pharmacology & therapeutics (01.05.2009)

Get full text

Journal Article

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

by Sieper, J., Kivitz, A., van Tubergen, A., Deodhar, A., Coteur, G., Woltering, F., Landewé, R.
Published in Arthritis care & research (2010) (01.10.2015)

Get full text

Journal Article

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

by Feagan, B. G., Sandborn, W. J., Wolf, D. C., Coteur, G., Purcaru, O., Brabant, Y., Rutgeerts, P. J.
Published in Alimentary pharmacology & therapeutics (01.03.2011)

Get full text

Journal Article

FRI0523 Validity of ankylosing spondylitis patient-reported outcome instruments in the broad axial spondyloarthritis population

FRI0523 Validity of ankylosing spondylitis patient-reported outcome instruments in the broad axial spondyloarthritis population

by van Tubergen, A., Black, P., McKenna, S. P., Coteur, G.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

THU0269 Validity and Responsiveness of the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) in A Randomised Controlled Clinical Trial

THU0269 Validity and Responsiveness of the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) in A Randomised Controlled Clinical Trial

by Kirwan, J., Coteur, G., Dures, E., Nicklin, J., Bryson, J., Hewlett, S.
Published in Annals of the rheumatic diseases (01.06.2014)

Get full text

Journal Article

Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol

Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol

by Feagan, B. G., Hanauer, S. B., Coteur, G., Schreiber, S.
Published in Alimentary pharmacology & therapeutics (01.05.2011)

Get full text

Journal Article

SAT0260 Effect of Certolizumab Pegol on the Multiple Facets of Psoriatic Arthritis as Reported by Patients with and without Prior Anti-Tnf Exposure: 24-Week Patient-Reported Outcome Results of Rapid-PSA Study

SAT0260 Effect of Certolizumab Pegol on the Multiple Facets of Psoriatic Arthritis as Reported by Patients with and without Prior Anti-Tnf Exposure: 24-Week Patient-Reported Outcome Results of Rapid-PSA Study

by Gladman, D., Fleischmann, R., Coteur, G., Woltering, F., Mease, P. J.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

SAT0165 Improvements in Patient-Reported Outcomes and Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study

SAT0165 Improvements in Patient-Reported Outcomes and Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study

by Emery, P., Bingham, C.O., Burmester, G.-R., Bykerk, V.P., Furst, D.E., Mariette, X., Purcaru, O., Coteur, G., VanLunen, B., Weinblatt, M.
Published in Annals of the rheumatic diseases (01.06.2015)

Get full text

Journal Article

Validity And Responsiveness Of The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) In A Randomized Controlled Clinical Trial

Validity And Responsiveness Of The Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) In A Randomized Controlled Clinical Trial

by Kirwan, J, Coteur, G, Dures, E, Nicklin, J, Bryson, J, Hewlett, S
Published in Value in health (01.11.2014)

Get full text

Journal Article

Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis with Certolizumab Pegol: 48-Week Patient-Reported Outcome Results of the Rapid-PsA Study

Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis with Certolizumab Pegol: 48-Week Patient-Reported Outcome Results of the Rapid-PsA Study

by Gladman, D, Fleischmann, R, Coteur, G, Peterson, L, Mease, P.J
Published in Value in health (01.11.2013)

Get full text

Journal Article

Effect Of Certolizumab Pegol On The Multiple Facets Of Psoriatic Arthritis As Reported By Patients: 24-Week Patient Reported Outcome Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study

Effect Of Certolizumab Pegol On The Multiple Facets Of Psoriatic Arthritis As Reported By Patients: 24-Week Patient Reported Outcome Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study

by Gladman, D, Fleischmann, R, Coteur, G, Woltering, F, Mease, P
Published in Value in health (01.05.2013)

Get full text

Journal Article

Validity Of Ankylosing Spondylitis Patient-Reported Outcome Instruments In The General Axial Spondyloarthritis Population

Validity Of Ankylosing Spondylitis Patient-Reported Outcome Instruments In The General Axial Spondyloarthritis Population

by van Tubergen, A, Black, P, McKenna, S, Coteur, G
Published in Value in health (01.05.2013)

Get full text

Journal Article

THU0360 Rapid Improvements in Patient-Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis: 24-Week Results of Rapid-Axspa Study

THU0360 Rapid Improvements in Patient-Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis: 24-Week Results of Rapid-Axspa Study

by Sieper, J., Kivitz, A., van Tubergen, A., Deodhar, A., Coteur, G., Woltering, F., Landewé, R.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

SAT0545 Comparing Health-Related Quality of Life across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data

SAT0545 Comparing Health-Related Quality of Life across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data

by Mease, P. J., van Tubergen, A., Deodhar, A., Coteur, G., Nurminen, T., van der Heijde, D.
Published in Annals of the rheumatic diseases (01.06.2013)

Get full text

Journal Article

FRI0004 Randomization to Patient-Reported RAPID3 versus Physician-Based CDAI Tools for Prediction of Treatment Response and Assessment of Patient-Reported Outcomes in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Results from the PREDICT Study

FRI0004 Randomization to Patient-Reported RAPID3 versus Physician-Based CDAI Tools for Prediction of Treatment Response and Assessment of Patient-Reported Outcomes in Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Results from the PREDICT Study

by Curtis, J.R., Churchill, M., Kivitz, A., Samad, A., Gauer, L., Coteur, G., Gervitz, L., Koetse, W., Melin, J., Yazici, Y.
Published in Annals of the rheumatic diseases (01.06.2014)

Get full text

Journal Article